European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma

Pier Luigi Zinzani, Lionel Karlin, John Radford, Dolores Caballero, Paul Fields, Martine E. D. Chamuleau, Francesco d’Amore, Corinne Haioun, Catherine Thieblemont, Eva González-Barca, Carlos Grande García, Peter W. Johnson, Gustaaf W. van Imhoff, Thomas Ng, Karen Dwyer, and Franck Morschhauser

Disclosures: Thomas Ng and Karen Dwyer are employees of ProStraken and Kyowa Kirin Pharmaceutical Development, Inc., respectively. The remaining authors recruited the patients into this clinical trial, which was supported by Kyowa Kirin Pharmaceutical Development, Inc. (Princeton, New Jersey).

Contributions: All of the authors had full access to all study data, contributed to writing the manuscript and its critical revision, and performed the research.